Business
Anti-Cancer MDK mRNA - Positive in vitro Results
Anti-Cancer MDK mRNA - Positive in vitro Results.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n\n13 June 2023\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\n \nAnti-Cancer MDK mRNA - Positive in vitro Results\nPositive Experimental Results in Breast and Liver Cancer and Enhanced mRNA Patent Position\n \nRoquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market is pleased to announce the successful completion of in vitro studies for the Company's anti-cancer mRNA therapeutic in breast and liver cancer. The studies demonstrated a statistically significant reduction in both proliferation (cancer growth) and migration.\n \nToday's announcement follows the development of a new platform of anti-cancer mRNA therapeutics targeting the Company's novel Midkine target (\"MDK mRNA Program\") announced on 8 March 2023. The Roquefort Therapeutics team and collaborators at the University of New South Wales have accelerated development of the MDK mRNA Program and successfully demonstrated its cancer killing ability in validated in vitro models of breast and liver cancer.\n \nThe Company's MDK mRNA Program was tested in validated in vitro models of breast and liver cancer to evaluate whether this could slow the cancer growth and migration (as an early proxy for metastasis). The study demonstrated a statistically significant reduction in both proliferation (cancer growth) and migration. While these are early in vitro results, this effect, if replicated in clinical trials, is consistent with the potential for a first in class cancer medicine. The Company intends to present these highly encouraging results at one of the forthcoming leading cancer conferences.\n \nThe Company has recently updated its filed patents to protect the MDK mRNA Program including compositions and methods, which further consolidates the Company's leadership position in the Midkine field.\n \nThe mRNA cancer market is a highly attractive new field of medicine (~$31 billion, 7.8% CAGR[1]) and is led by Pfizer, Moderna and BioNTech. Roquefort Therapeutics is well positioned in this field, with four mRNA sequences that uniquely target Midkine.\n \nThe Company's strategic focus is on solid cancers including breast and liver cancer in which poor survival is correlated to Midkine expression[2]. Bre...